Breast and Ovarian Cancer NGS panel

Genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CASP8, CDH1, CHEK2, FANCA, FANCC, FANCD2 (excluding exon 15), FANCE, FANCF, FANCG, KRAS, MAP3K1, MEN1, MLH1, MSH2, MSH6, MRE11A, MUTYH, NBN, PALB2, PTCH1, PTEN, RAD50, RAD51C, RAD51D, STK11, TGFB1, TP53, XRCC2

Price / TAT: 1051 EUR / 6-9 weeks

Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.


Ordering information: Go to online ordering or download sample submission form

Targeted mutation analysis

Genes: BRCA1, BRCA2, CHEK2, RAD51, NBN

No of
detectable
markers:
87

Lab method: DNA microarray (APEX – Arrayed Primer EXtension)

Price / TAT: 316 EUR / 2-4 weeks

Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

3 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.


Ordering information: Go to online ordering or download sample submission form

Indications for genetic testing:

1. Testing of individuals with early-age-onset of breast or ovarian cancer
2. Testing of individuals with family history of breast or ovarian cancer
3. Testing of at-risk family members for known mutations
3. Genetic counseling

Testing should be performed if there is a family history of breast or ovarian cancer, genetic alterations have been found in the family, or there is a history of breast cancer in males in the family.

Breast and ovarian cancers are most strongly associated with mutations of the BRCA1 and BRCA2 genes. Among women who have a clinically important BRCA gene mutation, the lifetime risk of developing breast and/or ovarian cancer can reach 80%. Cancer-predisposing mutations in the BRCA1 and BRCA2 genes are inherited in an autosomal dominant manner. The prognosis for breast cancer survival depends upon the stage at which breast cancer is diagnosed.